IREN Secures $3.65B Microsoft GPU Deal as Circle Slides 5.8% on Insider Selling

Crypto News IREN, an Australia-based AI infrastructure company that began as a Bitcoin mining operation, drew investor attention after securing a $3.65 billion investment-grade GPU financing facility tied to Microsoft. The deal is structured to fund the heavy GPU capital expenditure required to deliver an AI cloud contract with Microsoft, covering roughly 96% of the project's GPU spending and collateralized by the hardware and contracted cash flows. Shares climbed 5.4% to $59.77 and touched $60.36 in after-hours trade. The facility underpins IREN's plan to scale AI cloud capacity to 480 megawatts by the end of 2026 while keeping blended financing costs low. Alongside the financing package, IREN signed a separate agreement worth about $1.6 billion with Dell Technologies built around Nvidia Blackwell GPU systems, bundling servers, networking, storage and integration services. Management framed time-to-compute as a core competitive advantage, and the deal lifted the firm's projected annual revenue potential from roughly $3.7 billion to $4.4 billion. The company holds an 800-megawatt data center campus in Australia and has locked in four 330kV grid connections to power dense computing. The moves underline a deliberate transition from pure mining toward becoming a GPU cloud provider, with analysts setting an average price target of $82.62 against a stretched 124.5 price-to-earnings ratio. Circle Internet Group, the issuer of the USDC stablecoin, slid 5.8% to $77.85 as weak earnings collided with heavy insider selling and a governance shake-up. A recent SEC filing shows chief executive Jeremy Allaire sold 56,200 shares at an average $82.93, raising about $4.66 million under a Rule 10b5-1 plan, while president Heath Tarbert offloaded 39,240 shares. Over the past three months, insiders disposed of roughly 1.42 million shares worth about $120.1 million, though management still controls 10.85% of the company. The first-quarter print missed expectations at $0.21 per share against a $0.27 consensus, even as revenue rose 20% year over year to $694.13 million. The pressure extended to the boardroom, where Rajeev Date, a former U.S. regulator and fintech veteran, resigned with immediate effect; the filing named no successor or reason. On-chain data shows Circle moved roughly $4.4 billion in USDC to a Coinbase-managed wallet over the same window, the largest single transfer on record and a reminder of how tightly the two firms' liquidity operations are intertwined. One brokerage cut its price target to $85 from $135 while keeping a neutral stance. Circle continues to expand its payments network, extending stablecoin payouts and cross-border settlement to push deeper into programmable payments and corporate treasury use cases. In a development outside the digital-asset arena, the U.S. Food and Drug Administration approved AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic prostate cancer. The clearance rests on the Phase 3 CAPItello-281 trial, where the combination cut the risk of radiographic disease progression or death by 19%, with a hazard ratio of 0.81 and a p-value of 0.034. Median radiographic progression-free survival reached 33.2 months for the treatment arm versus 25.7 months for the control group. Overall survival data remain immature but trended in the drug's favor, the company said in its release. The FDA simultaneously cleared a companion diagnostic that detects PTEN deficiency, building a structure in which a targeted therapy and its biomarker test arrive together. The company estimates that about one in four eligible patients carry PTEN-deficient tumors, an independent risk factor for worse outcomes. TRUQAP, a first-in-class AKT inhibitor, now adds prostate cancer to an earlier breast-cancer indication. Safety remains a watch point: grade 3 or higher adverse events occurred in 67% of the combination arm, with rash and hyperglycemia most common, and 20% of patients discontinued treatment. A European regulatory review is underway, reinforcing a broader shift toward biomarker-driven precision oncology. Threaded together, these stories sketch a market sorting winners from the strained: a former Bitcoin miner repricing itself as an AI infrastructure platform, a leading stablecoin issuer absorbing insider exits and earnings pressure, and a pharma giant advancing precision medicine far from the blockchain. COINOTAG's aggregate data frames the crypto backdrop as defensive — our Fear and Greed Index sits at 13 of 100, deep in Extreme Fear, while Bitcoin dominance stands at 70.4% and total market capitalization holds near $1.83 trillion. With Bitcoin trading around $64,000, capital is concentrating in the largest names rather than altcoins, and investors are scrutinizing balance sheets — a posture that typically accompanies a defensive, bear market stance.